It was a big day for investors watching the race to create the next generation of hepatitis C drug cocktails. Most of the major players released data for the European Association for the Study of the Liver conference today.

In the segment below, health-care analyst David Williamson explains why small-cap Achillion has an uphill battle in front of it while attempting to dethrone big pharma and big biotech Goliaths. Watch and find out how Achillion disappointed investors today, but its real test is still ahead.

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.

The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.